Aug. 23rd, 2024: "We are looking forward to worki
Post# of 148112
"We are looking forward to working with Syneos Health to advance our Phase II study of leronlimab’s effects on chronic inflammation."
Sept. 9th, 2024:
"....we announced our selection of Syneos Health to serve as our clinical research organization (“CRO”) and implement our FDA-approved protocol to evaluate leronlimab in the treatment of patients with HIV and chronic inflammation."
" We will continue to provide updates on this trial in the coming weeks and expect to start screening patients in December 2024."